+1 877 705 191424 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 6Years +
All Genders
ID06039241

Prospective Observational Study on Long-term Treatment with Dupilumab in Patients Aged 6 Years and Older with Atopic Dermatitis

Led by Sanofi · Updated on 2026-02-12

900

Participants Needed

55

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are conducting a prospective, non-interventional observational study to understand how patients aged 6 years and older with atopic dermatitis AD respond to treatment with dupilumab in everyday medical practice. The study aims to characterize these patients by examining their medical history, demographic and disease-related features, associated allergic conditions, other type 2 inflammation diseases, and their past and current treatments. The study will also assess the long-term effectiveness and safety of dupilumab over two years, focusing on disease control and quality of life.

CONDITIONS

Brief Title

Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis

Who Can Participate

Age: 6Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients are at least 6 years of age at the baseline visit.
  • Initial treatment with dupilumab was started in adults and adolescents 12 years and older with moderate to severe atopic dermatitis.
  • Children aged 6 to 11 years with severe atopic dermatitis according to approved guidelines.
  • Patients or their guardians can understand and complete study questionnaires.
  • Signed written informed consent before starting study documentation, including consent from parents or guardians if applicable.
Not Eligible

You will not qualify if you...

  • Patients with a contraindication for dupilumab based on current medical guidelines.
  • Patients who have already been treated with dupilumab for more than 7 days.
  • Having any acute or chronic disease that may prevent completing questionnaires or affect study results, as judged by the doctor.
  • Participation in another ongoing interventional or observational study that could affect this study's assessment, as judged by the doctor.

Research Team

T

Trial Transparency email recommended (Toll free for US & Canada)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here